Northwest Biotherapeutics Files 8-K
Ticker: NWBO · Form: 8-K · Filed: 2024-06-04T00:00:00.000Z
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
NWBO signed a big deal, filing an 8-K on 5/31.
AI Summary
On May 31, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Bethesda, Maryland, filed this 8-K report on June 4, 2024.
Why It Matters
This filing indicates a significant new agreement for Northwest Biotherapeutics, which could impact its operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, requiring further analysis of the agreement's terms.
Key Players & Entities
- Northwest Biotherapeutics, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
- June 4, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Bethesda, Maryland (location) — Principal executive offices
FAQ
What type of material definitive agreement did Northwest Biotherapeutics enter into?
The filing states that the report is for an 'Entry into a Material Definitive Agreement' but does not specify the nature of the agreement within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 31, 2024.
What is the principal business address of Northwest Biotherapeutics, Inc.?
The principal executive offices are located at 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.
What is the SEC file number for Northwest Biotherapeutics, Inc.?
The SEC file number is 0-35737.
What is the IRS Employer Identification Number for Northwest Biotherapeutics, Inc.?
The IRS Employer Identification Number is 94-3306718.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-06-04 17:11:16
Key Financial Figures
- $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
- $0.40 — Company's common stock at forty cents ($0.40) per share based on certain terms initi
- $3,250,000 — une 5, 2024. The gross proceeds will be $3,250,000. The funds will be used for the Company
Filing Documents
- tm2416435d1_8k.htm (8-K) — 21KB
- 0001104659-24-068314.txt ( ) — 187KB
- nwbo-20240531.xsd (EX-101.SCH) — 3KB
- nwbo-20240531_lab.xml (EX-101.LAB) — 33KB
- nwbo-20240531_pre.xml (EX-101.PRE) — 22KB
- tm2416435d1_8k_htm.xml (XML) — 4KB
01
Item 1.01. Entry into a Material Definitive Agreement. On June 4, 2024, Northwest Biotherapeutics, Inc. (the "Company") entered into a Stock Purchase Agreement (SPA) with SIO Capital Management LLC, for SIO's purchase of eight million, one hundred twenty-five thousand (8,125,000) shares of the Company's common stock at forty cents ($0.40) per share based on certain terms initially negotiated on May 31, 2024. The transaction is expected to close on June 5, 2024. The gross proceeds will be $3,250,000. The funds will be used for the Company's ongoing business operations. Joseph Gunnar & Co., LLC acted as placement agent. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: June 4, 2024 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman